Moderna, Inc. 四季度营收为6.78亿美元,而分析师的平均预期为6.261亿美元,主要得益于其新冠疫苗在美国的销售好于预期。
公司正在开发更新的产品,以填补收入缺口,并证明其 mRNA 技术的长期可行性。
Moderna重申了2026年收入增长10%的预期。
Moderna, Inc. 四季度营收为6.78亿美元,而分析师的平均预期为6.261亿美元,主要得益于其新冠疫苗在美国的销售好于预期。
公司正在开发更新的产品,以填补收入缺口,并证明其 mRNA 技术的长期可行性。
Moderna重申了2026年收入增长10%的预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.